BONE THERAPEUTICS: Increased financial visibility out to Q3 2020 | CORPORATE | EUR7.3 vs. EUR7,4 (+94%)
BONE THERAPEUTICS - CORPORATE | EUR7.3 vs. EUR7,4 (+94%)Increased financial visibility out to Q3 2020
EUR8.5m raised in a mix of equity and debt
Financial runway extended to QQ 2020
Limited dilution, new FV of EUR7.3 (vs EUR7.4)
Bone Therapeutics is a biotechnology company with an advanced clinical pipeline of cell products for orthopaedic conditions and bone diseases (two Phase II/III and three Phase I/II clinical studies). These areas are characterized by high unmet medical needs due to the lack of efficacious and safe, non-invasive, treatments. Co. has two products in clinical trials, its allogeneic bone cell therapy product, ALLOB®, and its autologous bone cell therapy product, PREOB®. Co. is also conducting preclinical research on next generation products, such as combined cell-matrix products for large bone defects and maxillofacial.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.